PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1747485
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1747485
Nasal Cannula Market is estimated to be valued at USD 8.71 Bn in 2025 and is expected to reach USD 13.45 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 8.71 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 6.40% | 2032 Value Projection: | USD 13.45 Bn |
The nasal cannula device is used to deliver oxygen to patients with respiratory diseases such as asthma, lung cancer, pneumonia, Chronic Obstructive Pulmonary Diseases (COPD), and pulmonary fibrosis. This device is made up of plastic or silicon material and has a tube-like structure with two prongs to connect nostrils for providing oxygen. These tubes are placed behind the ear to allow for better adjustment of the prongs. These nasal cannula tubes are available at a low cost, which drives the growth of the nasal cannula market. There are different types of nasal cannulas available in the market which are used for pre-mature infants, adults suffering from respiratory diseases, patients with lung cancer, or patients with respiratory failure due to COVID-19.
Market players are indulged in inorganic activities such as collaborations in order to increase research and development activities for the treatment of respiratory diseases. This is expected to increase the growth of the global nasal cannula market over the forecast period. For instance, on February 17, 2021, Vir Biotechnology and GSK expanded their coronavirus collaboration to develop advanced therapeutics for influenza and respiratory viruses. Vir Biotechnology is immunology focused company aims for developing technologies for infectious diseases and GSK is manufacturer of vaccines, innovative medicines and healthcare products. The aim of this collaboration is to use Vir's monoclonal antibody technology to create an identical new anti-viral antibodies for therapeutic treatments and preventions for COVID -19 or future outbreaks of the pathogenic diseases.
Increasing awareness for the treatment as well as management of respiratory diseases is expected to increase the growth of the global nasal cannula market over the forecast period. For instance, a news published on September 9, 2021 by AstraZeneca is a global pharmaceutical business company and manufacturer of innovative medicines has launched program called as International Respiratory Coalition for Urgent need for national respiratory strategies after COVID-19 to drive the improvements in healthcare systems resilience. It is coordinated with European Respiratory Society .This program will provide funding or contribution with expertise for delivering facilities to patients suffering for respiratory diseases.
Key features of the study